New drug duo takes on rare sarcomas

NCT ID NCT03282344

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether combining NKTR-214 and nivolumab can shrink or control advanced sarcoma that has spread. About 88 people aged 12 and older with certain sarcoma types will receive both drugs every three weeks. The main goal is to see how many patients have their tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NKTR-214 and nivolumab
What this could lead to: If it works, this combination could offer a new treatment option for advanced sarcoma, helping to shrink or control tumors.
What could go wrong: This is a small, early-phase pilot study. The drugs may not work for all sarcoma types, and side effects like immune reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma angiosarcoma chondrosarcoma leiomyosarcoma osteosarcoma sarcoma synovial sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.